|By PR Newswire||
|March 19, 2014 07:45 AM EDT||
NASDAQ: CRME TSX: COM
VANCOUVER, March 19, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the company has entered into a distribution agreement with Logista Pharma S.A., headquartered in Madrid, Spain, to distribute BRINAVESS™ (vernakalant IV) within the Spanish market.
"We are pleased to have entered into this agreement with Logista Pharma to distribute BRINAVESS to our Spanish customers," said Karim Lalji, Cardiome's Chief Commercial Officer. "BRINAVESS pricing has been approved nationally by La Comisión Interministerial de Precios de los Medicamentos, Spain's official medical drug pricing and reimbursement agency, which is significant for gaining market acceptance. Spain is a key growth market for BRINAVESS and our new relationship with Logista Pharma is one of many steps towards building a successful brand in this country."
The state-of-the-art processes developed by Logista Pharma will ensure secure and timely fulfillment of BRINAVESS orders to all our hospital customers.
Financial details of the agreement were not disclosed.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. Cardiome has two marketed, in-hospital, cardiology products, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in Acute Coronary Syndrome patients.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2014 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
SOURCE Cardiome Pharma Corp.
Dec. 10, 2016 07:00 PM EST Reads: 4,121
Dec. 10, 2016 06:45 PM EST Reads: 1,072
Dec. 10, 2016 06:30 PM EST Reads: 997
Dec. 10, 2016 06:30 PM EST Reads: 1,938
Dec. 10, 2016 06:30 PM EST Reads: 1,517
Dec. 10, 2016 06:15 PM EST Reads: 1,045
Dec. 10, 2016 05:30 PM EST Reads: 974
Dec. 10, 2016 05:15 PM EST Reads: 2,355
Dec. 10, 2016 05:15 PM EST Reads: 1,392
Dec. 10, 2016 04:30 PM EST Reads: 1,347
Dec. 10, 2016 04:30 PM EST Reads: 1,811
Dec. 10, 2016 04:30 PM EST Reads: 1,901
Dec. 10, 2016 03:45 PM EST Reads: 902
Dec. 10, 2016 03:45 PM EST Reads: 1,317
"At ROHA we develop an app called Catcha. It was developed after we spent a year meeting with, talking to, interacting with senior citizens watching them use their smartphones and talking to them about how they use their smartphones so we could get to know their smartphone behavior," explained Dave Woods, Chief Innovation Officer at ROHA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 10, 2016 03:30 PM EST Reads: 917